Data supplements
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- The Role of Total-Body PET in Drug Development and Evaluation: Status and Outlook
- Identifying secondary findings in PET/CT reports in oncological cases: A quantifying study using automated Natural Language Processing
- Choice Is Good at Times: The Emergence of [64Cu]Cu-DOTATATE-Based Somatostatin Receptor Imaging in the Era of [68Ga]Ga-DOTATATE
- A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- 64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial
- A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors
- 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
- Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
- Aetna and 68Ga-DOTATATE: A Sequel to "The Injustice of Being Judged by the Errors of Others" (1)
- Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
- Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented